Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form 4

ACHILLION Form 4 August 15, 20	PHARMACE	UTICALS	INC								
Check this if no longe subject to Section 16 Form 4 or Form 5 obligation may contin See Instruct	hington, ¹ GES IN E SECURI	D.C. 205 BENEFI TIES Securiti ing Com	549 CIAI es Ex pany	L OW schang Act o	COMMISSION NERSHIP OF ge Act of 1934, f 1935 or Sectio 40	OMB Number: Expires: Estimated a burden hou response	irs per				
1(b).											
(Print or Type R	esponses)										
FRASHIER GARY E St			Symbol ACHILI	ACHILLION PHARMACEUTICALS INC				5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_ Director 10% Owner			
(Last) (First) (Middle) 3. Date of (Month/D C/O ACHILLION 08/13/20 PHARMACEUTICALS, INC., 300 GEORGE STREET								Officer (give titleOther (specify below)			
Filed(Mont				endment, Date Original nth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
	EN, CT 06511	(7)						Person	whole than one K	cporting	
(City) 1.Title of Security (Instr. 3)	.Title of 2. Transaction Date 2A. Deemed Security (Month/Day/Year) Execution Dat		emed on Date, if	3. Transactio Code (Instr. 8)	4. Securi nAcquired Disposed (Instr. 3,	ties l (A) o l of (D 4 and (A) or	or)) 5)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	lly Owned 7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	08/13/2014			Code V M	Amount 5,000	(D) A	Price \$ 3.1	10,000	D		
Common Stock	08/13/2014			S	5,000	D	\$8	5,000	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	Transaction of Derivative Code Securities		cisable and bate /Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	\$ 3.1	08/13/2014		М	5,000	<u>(1)</u>	12/16/2020	Common Stock	5,000

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
FRASHIER GARY E C/O ACHILLION PHARMACEUTICAI 300 GEORGE STREET NEW HAVEN, CT 06511	LS, INC.	X				
Signatures						
/s/ Mary Kay Fenton, attorney-in-fact	08/15/20	14				
<u>**</u> Signature of Reporting Person	Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option was grant on December 16, 2010 and vested as to 25% on the date of grant and as to an additional 2.08% at the end of each monthly period thereafter.

Remarks:

The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Frashier on Jun

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.